类风湿关节炎患者的阿达木单抗脱敏治疗一例

Adalimumab desensitization of rheumatoid arthritis:a case report

阿达木单抗是治疗类风湿关节炎等自身免疫性疾病的新型生物制剂,若发生过敏反应,将会影响后续治疗,或可使用脱敏疗法,抑制过敏的发生。本文对1例类风湿关节炎患者使用阿达木单抗致敏的原因进行分析,并行脱敏治疗,从0.5 mg逐渐增加剂量,直至累积剂量为40 mg,期间未发生过敏反应,后恢复为阿达木单抗全剂量使用,也未再出现过敏反应,提示脱敏成功。本例为阿达木单抗过敏患者提供一种切实可行的处理方案,对于临床有效开展生物制剂的过敏反应防治具有一定的借鉴意义。

Adalimumab is a new biological agent for the treatment of autoimmune diseases such as rheumatoid arthritis.If an allergic reaction occurs,it will affect the subsequent treatment,or desensitization therapy can be used to inhibit the occurrence of allergy.This paper analyzed the causes of sensitization with adalimumab in a patient with rheumatoid arthritis,and the desensitization treatment was performed.The dose was gradually increased from 0.5 mg until the cumulative dose of 40mg.No allergic reaction occurred,and recovered to the full dose of adalimumab,and there was no allergic reaction,indicating that the patient had successful desensitization.This case provides a practical treatment scheme for patients with adalimumab allergy,which has certain reference significance for clinical to effectively develop allergy prevention and control of biological agents.